General considerations for anticoagulation in patients with obesity

In patients with obesity (body mass index [BMI] of 30 kg/m² or more), evidence is limited to guide the choice of anticoagulant and the dosing of unfractionated heparin (UFH), low molecular weight heparin (LMWH) (eg enoxaparin, dalteparin) and direct-acting oral anticoagulants (DOACs) (eg apixaban, rivaroxaban, dabigatran).